Form 8-K - Current report:
SEC Accession No. 0001628280-22-004915
Filing Date
2022-03-03
Accepted
2022-03-03 16:18:21
Documents
15
Period of Report
2022-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20220303.htm   iXBRL 8-K 55112
2 EX-4.1 ex41formofpre-fundedwarrant.htm EX-4.1 112641
3 EX-10.1 ex101securitiespurchaseagr.htm EX-10.1 196517
4 EX-10.2 ex102registrationrightsagr.htm EX-10.2 160248
  Complete submission text file 0001628280-22-004915.txt   765950

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220303.xsd EX-101.SCH 1908
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220303_lab.xml EX-101.LAB 25948
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220303_pre.xml EX-101.PRE 13681
9 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220303_htm.xml XML 11883
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22709011
SIC: 2836 Biological Products, (No Diagnostic Substances)